Guardant Health Inc. has partnered with AstraZeneca PLC to develop a diagnostic test to go along with the Cambridge, U.K.-based company's non-small cell lung cancer drug Tagrisso.
The blood test, called a companion diagnostic because it corresponds to a specific treatment, is based on Guardant's platform Guardant360, and helps identify non-small cell lung cancer, or NSCLC, patients who might respond well to Tagrisso.
Guardant and AstraZeneca did not reveal the financial terms of the partnership.
Also part of the deal, Guardant plans to use its GuardantOmni platform as a companion diagnostic to AstraZeneca's Imfinzi, also for NSCLC.
The door is also open for more diagnostics from Guardant to be used for AstraZeneca's other programs, Guardant said in a Dec. 13 press release.
"Precision medicine is at the heart of our ambition to eliminate cancer as a cause of death," said Ruth March, senior vice president of precision medicine and genomics at AstraZeneca. "We are committed to matching life-changing medicines to patients most likely to benefit, and we believe our partnership with Guardant Health will help us achieve this."